Arbutus Biopharma Corp
ABUS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001447028
No open-market purchases or sales by Arbutus Biopharma Corp insiders were filed in the last 90 days; 176 institutions reported holding it in 13F filings for Q2 2026, worth $674.9M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Arbutus Biopharma Corp as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 91
- −3 vs. Q1 2021
- Shares held
- 28.9M
- +2.90M (+11.2%) vs. Q1 2021
- Total value
- $87.6M
- +$1.17M (+1.4%) vs. Q1 2021
- New holders
- 19
- 22 more added
- Sold out
- 22
- 25 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ABUS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 176 | $674.9M |
| Q1 2026 | 167 | $625.4M |
| Q4 2025 | 172 | $586.9M |
| Q3 2025 | 166 | $536.4M |
| Q2 2025 | 163 | $365.0M |
| Q1 2025 | 168 | $390.1M |
| Q4 2024 | 154 | $340.3M |
| Q3 2024 | 144 | $389.2M |
| Q2 2024 | 131 | $298.4M |
| Q1 2024 | 119 | $215.2M |
| Q4 2023 | 112 | $197.4M |
| Q3 2023 | 99 | $143.8M |
| Q2 2023 | 111 | $152.4M |
| Q1 2023 | 122 | $189.3M |
| Q4 2022 | 114 | $126.3M |
| Q3 2022 | 127 | $89.1M |
| Q2 2022 | 113 | $120.0M |
| Q1 2022 | 119 | $130.6M |
| Q4 2021 | 123 | $154.4M |
| Q3 2021 | 100 | $149.8M |
| Q2 2021 | 91 | $87.6M |
| Q1 2021 | 94 | $86.5M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Arbutus Biopharma Corp; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Woodline Partners LP | 0 | $0 | 0.00% | −78,339−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −72,500−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −42,171−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −29,880−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −24,210−100.0% | Sold out |
| Jefferies Group LLC | 0 | $0 | 0.00% | −14,100−100.0% | Sold out |
| Benjamin F. Edwards & Company, Inc. | 0 | $0 | 0.00% | −13,900−100.0% | Sold out |
| QCM Cayman, Ltd. | 0 | $0 | 0.00% | −12,728−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −12,719−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −12,147−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −11,890−100.0% | Sold out |
| SG3 Management, LLC | 0 | $0 | 0.00% | −11,264−100.0% | Sold out |
| Sowell Financial Services LLC | 0 | $0 | 0.00% | −1,475−100.0% | Sold out |